Results
Alembic Pharmaceuticals Q4 FY26 Results Conference Call
Alembic Pharmaceuticals reported Q4 revenue of INR1,838 crores, up 4% YoY, with EBITDA before R&D at INR455 crores and margins at 25%.
Management provided FY27 guidance targeting low double-digit cons
